194P Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)
| Autor: | Marmé, F., Rugo, H.S., Tolaney, S.M., Bardia, A., Schmid, P., Verret, W., Valdez, T., Wang, H., Cortés, J. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|